EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors

Javier García-Abellán iD, José A García iD, Sergio Padilla iD, Marta Fernández-González iD, Vanesa Agulló iD, Paula Mascarell iD, Ángela Botella, Félix Gutiérrez, Mar Masiá iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae383 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Javier García-Abellán und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Alicante, Spain. Hauptthemen laut MEDLINE: Carotid Intima-Media Thickness, Atherosclerosis, Disease Progression, HIV Infections. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish National Plan for Scientific and Technical Research and Innovation, European Regional Development Fund, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of integrase strand transfer inhibitors (INSTI) in the cardiovascular risk of people with HIV is controversial.

Objectives

To assess the association of INSTI to subclinical atherosclerosis progression measured with the carotid intima-media thickness (cIMT).

Methods

Prospective study in virologically suppressed people with HIV receiving INSTI- or NNRTI-based regimens. cIMT was measured at baseline, 48 and 96 weeks. cIMT progression was analysed both as a continuous and categorical variable, defined as cIMT increase ≥ 10% and/or new carotid plaque. Adjustments through Cox proportional hazard regression and linear mixed models, and propensity score matching were conducted.

Results

190 participants were recruited and 173 completed the 96 week follow-up. 107 (56.3%) were receiving an INSTI-containing, 128 (67.4%) a NNRTI-containing and 45 (23.7%) a NNRTI plus an INSTI-containing regimen. The overall median (IQR) 2-year change of cIMT was 0.029 (−0.041 to 0.124) mm; 87 (45.8%) participants experienced a cIMT increase ≥ 10%, of whom 54 (28.4%) developed a new carotid plaque. Adjusted Cox regression showed no differences between INSTI and NNRTI groups in the categorical 2-year progression of cIMT, both including or excluding participants receiving INSTI + NNRTI. Similar results were observed for the continuous cIMT increase through adjusted linear mixed models. Propensity score matching showed no significant differences in the 2 year cIMT change between treatment groups [0.049 mm (−0.031–0.103) in the INSTI group versus 0.047 mm (−0.023–0.115) in the NNRTI group; P = 0.647]. cIMT progression was associated with traditional cardiovascular risk factors.

Conclusions

INSTI-based regimens are not associated with increased progression of subclinical atherosclerosis when compared to NNRTI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carotid Intima-Media ThicknessAtherosclerosisDisease ProgressionHIV InfectionsReverse Transcriptase InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesAdultHIV Integrase Inhibitors

Substanzen

Reverse Transcriptase InhibitorsHIV Integrase Inhibitors

Autor:innen und Institutionen

  • Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Alicante, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.

ORCID-Profile: Javier García-Abellán, José A García, Sergio Padilla, Marta Fernández-González, Vanesa Agulló, Paula Mascarell, Mar Masiá

Förderung

  • Spanish National Plan for Scientific and Technical Research and Innovation
  • European Regional Development Fund
  • Instituto de Salud Carlos III
  • Consorcio Centro de Investigación Biomédica en Red
  • Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and European Union-NextGenerationEU
  • UMH-FISABIO
  • Generalitat Valenciana
  • Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana

Zitieren

APA

García-Abellán, J., García, J. A., Padilla, S., Fernández-González, M., Agulló, V., Mascarell, P., Botella, Á., Gutiérrez, F., & Masiá, M. (2025). No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae383

Vancouver

García-Abellán J, García JA, Padilla S, Fernández-González M, Agulló V, Mascarell P, et al. No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae383

BibTeX
@article{GarcaAbelln2025,
  author = {García-Abellán, Javier and García, José A and Padilla, Sergio and Fernández-González, Marta and Agulló, Vanesa and Mascarell, Paula and Botella, Ángela and Gutiérrez, Félix and Masiá, Mar},
  title = {No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae383}
}
Kostenlos starten →